Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation
Clinical trial NCT02252146 · COMPLETED
Trial details
- NCT number
- NCT02252146
- Sponsor
- Idera Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-06-01
- Primary completion
- 2016-12-01
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.